FDA Oks first-line use of travoprost
December 1st 2010The FDA has approved Alcon Laboratories' travoprost ophthalmic solution 0.004% formulated with a proprietary ionic-buffered preservative system for first-line treatment to reduce elevated IOP in patients with ocular hypertension or open-angle glaucoma.